BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

RYTMRhythm Pharmaceuticals2026-07-21 12:00 EST

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

BLTEBelite Bio2026-08-06 12:00 EST

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

MISTMilestone Pharmaceuticals Inc.2026-09-02 12:00 EST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MISTMilestone Pharmaceuticals Inc.2026-08-27 12:00 EST

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
0.92 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States